Transcranial Magnetic Stimulation for Apathy in Mild Cognitive Impairment (TAMCI)
Primary Purpose
Apathy, Mild Cognitive Impairment, Transcranial Magnetic Stimulation
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Transcranial Magnetic Stimulation
Sponsored by
About this trial
This is an interventional treatment trial for Apathy
Eligibility Criteria
Inclusion Criteria:
- meeting the modified Mayo Clinic criteria for MCI
- Having caregivers
- apathy threshold (NPI)
- MMSE 23
- On stable dose of antidepressants for at least a month (if applicable)
Exclusion Criteria:
PHASE I
- Uncontrolled diabetes mellitus (Fasting BS>200mg/dl, HbA1c>10)
- Renal disease requiring dialysis
- Uncontrolled blood pressure (>160/100, <100 systolic)
- Metastatic cancer or undergoing chemotherapy
- Deep venous thrombosis or myocardial infarction in past 3 months
- Uncontrolled malignant cardiac arrhythmia
- Cerebral aneurysm or intracranial bleed in past year
- Unstable angina in past month
- Unstable abdominal or thoracic aortic aneurysm (>4cm)
- End-stage congestive heart failure
EXCLUSIONARY DUE TO rTMS: ALL PHASE II AND SUBSET OF PHASE I THAT RECEIVE SINGLE SESSION rTMS
- Taking medications known to increase risk of seizures from 2012 Beers criteria such as bupropion, chlorpromazine, clozapine.
- Taking other medications known to increase risk of seizures such as tricyclic antidepressants.
- Taking ototoxic medications: Aminoglycosides, Cisplatin
- History of seizures/ seizures in first degree relatives
- Those with implanted device
- History of stroke, aneurysm, or cranial neurosurgery
- History of bipolar disorder
- Current alcohol related disorder needing medical treatment
- History of Tourette's syndrome or presence of motor tics
- History of abnormal electroencephalogram (EEG)
EXCLUSIONARY DUE TO CONFOUNDING WITH APATHY: PHASE II
- Current episode of Major Depressive Disorder
- Current use of stimulants
- Change in dose of dementia medications within 30 days
- Change in dose of antidepressants within 30 days
Sites / Locations
- Central Arkansas Veterans Healthcare System Eugene J. Towbin Healthcare Center, Little Rock, ARRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
No Intervention
Active Comparator
Sham Comparator
Arm Label
Apathy +, rTMS -
rTMS
Sham
Arm Description
This arm will be followed without intervention
This group will be randomized to receive rTMS treatment
This group will be randomized to receive sham treatment
Outcomes
Primary Outcome Measures
Change in Apathy Evaluation Scale Score
Range 18-72 Lower score is improvement
Secondary Outcome Measures
Change in Modified Mini Mental State Examination Score
Range 0-100 Higher score is improvement
Change in Conner's Continuous Performance Test Commission Error percentage
Range 0-100% Higher score is improvement
Full Information
NCT ID
NCT03590327
First Posted
May 15, 2018
Last Updated
October 18, 2022
Sponsor
VA Office of Research and Development
Collaborators
Central Arkansas Veterans Healthcare System, University of Arkansas
1. Study Identification
Unique Protocol Identification Number
NCT03590327
Brief Title
Transcranial Magnetic Stimulation for Apathy in Mild Cognitive Impairment
Acronym
TAMCI
Official Title
Transcranial Magnetic Stimulation for Apathy in Mild Cognitive Impairment
Study Type
Interventional
2. Study Status
Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
November 1, 2018 (Actual)
Primary Completion Date
September 30, 2023 (Anticipated)
Study Completion Date
September 30, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
VA Office of Research and Development
Collaborators
Central Arkansas Veterans Healthcare System, University of Arkansas
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Apathy, a profound loss of initiative and motivation, is often seen in older Veterans with memory problems. Apathy leads to serious health problems, increases dependency, and caregiver burden. If untreated, apathy hastens the progression to frank dementia. In a pilot study, the investigators found that apathy, working memory, and function can be restored using magnetic stimulation in some but not all older Veterans. The reason for this variation is unknown. The investigators propose a three-phase study in 125 older Veterans with mild memory problems. Their motivation, memory, and function will be measured periodically. Veterans with apathy that are eligible for treatment will receive either real or sham magnetic stimulation to the front part of their brain over 20 sessions. Genetic testing and biomarkers will be used to differentiate those who respond to magnetic stimulation from those who do not. Impact on function, quality of life, and rates of progression to dementia will also be studied.
A project modification was obtained to conduct a cross-sectional study, the COVID Dementia study. The cross-sectional study will examine the effect of the pandemic on MCI and AD patients and their caregivers ("individual COVID-related factors" such as, personally infected, death of a friend/family member, economic hardship, disruption in care, isolation), barriers to telehealth, caregiver distress, NPS, cognition (including onset of delirium), and function. Our goal is to develop a multi-pronged, remotely deliverable intervention to address consequences of healthcare disruptions in older Veterans with cognitive impairment.
Aim 1. To explore the association between COVID-related factors and neuropsychiatric symptoms in individuals with MCI and AD. Hypothesis: The number of COVID-related factors endorsed by caregivers will be positively correlated with the severity of NPI-Q in individuals with MCI and AD.
Aim 2. To assess cognition (telephonic version of the Montreal Cognitive Assessment; tMoCA12, and daily function (Functional Activities Questionnaire; FAQ13). Hypothesis: The number of COVID-related factors will be positively correlated with the severity of cognitive and functional deficits in individuals with MCI and AD.
Aim 3. To explore the associations among COVID-related factors and caregiver distress. Hypothesis: Caregiver resilience and perceived social support will modify the association between COVID-related factors and severity of distress in caregivers.
Detailed Description
Apathy, a profound loss of initiative and motivation, is often seen in older Veterans with memory problems. Apathy leads to serious health problems, increases dependency, and caregiver burden. If untreated, apathy hastens the progression to frank dementia. In a pilot study, the investigators found that apathy, working memory, and function can be restored using magnetic stimulation in some but not all older Veterans. The reason for this variation is unknown. The investigators propose a three-phase study in 125 older Veterans with mild cognitive impairment. Their motivation, other behavioral problems, memory, and function will be measured periodically. Veterans with apathy that are eligible for treatment will receive either real or sham magnetic stimulation to the dorsolateral prefrontal cortex over 20 daily sessions on consecutive week days. Genetic testing and biomarkers will be used to differentiate those who respond to magnetic stimulation from those who do not. Impact on function, quality of life, and rates of progression to dementia will also be studied.
A project modification was obtained to conduct a cross-sectional study, the COVID Dementia study. The cross-sectional study will examine the effect of the pandemic on MCI and AD patients and their caregivers ("individual COVID-related factors" such as, personally infected, death of a friend/family member, economic hardship, disruption in care, isolation), barriers to telehealth, caregiver distress, NPS, cognition (including onset of delirium), and function. Our goal is to develop a multi-pronged, remotely deliverable intervention to address consequences of healthcare disruptions in older Veterans with cognitive impairment.
Aim 1. To explore the association between COVID-related factors and neuropsychiatric symptoms in individuals with MCI and AD. Hypothesis: The number of COVID-related factors endorsed by caregivers will be positively correlated with the severity of NPI-Q in individuals with MCI and AD.
Aim 2. To assess cognition (telephonic version of the Montreal Cognitive Assessment; tMoCA12, and daily function (Functional Activities Questionnaire; FAQ13). Hypothesis: The number of COVID-related factors will be positively correlated with the severity of cognitive and functional deficits in individuals with MCI and AD.
Aim 3. To explore the associations among COVID-related factors and caregiver distress. Hypothesis: Caregiver resilience and perceived social support will modify the association between COVID-related factors and severity of distress in caregivers.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Apathy, Mild Cognitive Impairment, Transcranial Magnetic Stimulation, Loneliness, COVID, Neuropsychiatric Symptoms
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
125 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Apathy +, rTMS -
Arm Type
No Intervention
Arm Description
This arm will be followed without intervention
Arm Title
rTMS
Arm Type
Active Comparator
Arm Description
This group will be randomized to receive rTMS treatment
Arm Title
Sham
Arm Type
Sham Comparator
Arm Description
This group will be randomized to receive sham treatment
Intervention Type
Device
Intervention Name(s)
Transcranial Magnetic Stimulation
Intervention Description
rTMS
Primary Outcome Measure Information:
Title
Change in Apathy Evaluation Scale Score
Description
Range 18-72 Lower score is improvement
Time Frame
2 weeks, 6 weeks, 6 months, 12 months, 24 months, 36 months, and 48 months
Secondary Outcome Measure Information:
Title
Change in Modified Mini Mental State Examination Score
Description
Range 0-100 Higher score is improvement
Time Frame
2 weeks, 6 weeks, 6 months, 12 months, 24 months, 36 months, and 48 months
Title
Change in Conner's Continuous Performance Test Commission Error percentage
Description
Range 0-100% Higher score is improvement
Time Frame
2 weeks, 6 weeks, 6 months, 12 months, 24 months, 36 months, and 48 months
Other Pre-specified Outcome Measures:
Title
Neuropsychiatric Inventory - Questionnaire
Description
To study the impact of COVID pandemic on neuropsychiatric symptoms of dementia. This outcome measure has questions pertaining to twelve neuropsychiatric symptoms seen in dementia. An aggregate score of the symptoms, caregiver distress and change during the COVID pandemic will be reported.
Presence or lack of each domain is reported for this study. No range in score for this scale.
Time Frame
Through study completion, an average of 1 year
Title
Functional Activities Questionnaire
Description
Measure of functional independence Range: 0-30 Higher score indicates higher dependence
Time Frame
Through study completion, an average of 1 year
Title
UCLA Loneliness scale
Description
Measures loneliness Range 3-9 Higher score indicates higher loneliness
Time Frame
Through study completion, an average of 1 year
Title
T-MoCA
Description
Measures global cognition Range: 0-22 Higher scores indicate better cognition
Time Frame
Through study completion, an average of 1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
meeting the modified Mayo Clinic criteria for MCI
Having caregivers
apathy threshold (NPI)
MMSE 23
On stable dose of antidepressants for at least a month (if applicable)
Exclusion Criteria:
PHASE I
Uncontrolled diabetes mellitus (Fasting BS>200mg/dl, HbA1c>10)
Renal disease requiring dialysis
Uncontrolled blood pressure (>160/100, <100 systolic)
Metastatic cancer or undergoing chemotherapy
Deep venous thrombosis or myocardial infarction in past 3 months
Uncontrolled malignant cardiac arrhythmia
Cerebral aneurysm or intracranial bleed in past year
Unstable angina in past month
Unstable abdominal or thoracic aortic aneurysm (>4cm)
End-stage congestive heart failure
EXCLUSIONARY DUE TO rTMS: ALL PHASE II AND SUBSET OF PHASE I THAT RECEIVE SINGLE SESSION rTMS
Taking medications known to increase risk of seizures from 2012 Beers criteria such as bupropion, chlorpromazine, clozapine.
Taking other medications known to increase risk of seizures such as tricyclic antidepressants.
Taking ototoxic medications: Aminoglycosides, Cisplatin
History of seizures/ seizures in first degree relatives
Those with implanted device
History of stroke, aneurysm, or cranial neurosurgery
History of bipolar disorder
Current alcohol related disorder needing medical treatment
History of Tourette's syndrome or presence of motor tics
History of abnormal electroencephalogram (EEG)
EXCLUSIONARY DUE TO CONFOUNDING WITH APATHY: PHASE II
Current episode of Major Depressive Disorder
Current use of stimulants
Change in dose of dementia medications within 30 days
Change in dose of antidepressants within 30 days
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Prasad R Padala, MBBS MBBS
Phone
(501) 257-2537
Email
Prasad.Padala@va.gov
First Name & Middle Initial & Last Name or Official Title & Degree
Christopher M Parkes, BS
Phone
(501) 257-2504
Email
christopher.parkes@va.gov
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Prasad R. Padala, MBBS MBBS
Organizational Affiliation
Central Arkansas Veterans Healthcare System Eugene J. Towbin Healthcare Center, Little Rock, AR
Official's Role
Principal Investigator
Facility Information:
Facility Name
Central Arkansas Veterans Healthcare System Eugene J. Towbin Healthcare Center, Little Rock, AR
City
North Little Rock
State/Province
Arkansas
ZIP/Postal Code
72114-1706
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Richard R Owen, MD
Phone
501-257-1710
Email
Richard.Owen2@va.gov
First Name & Middle Initial & Last Name & Degree
Prasad R. Padala, MBBS MBBS
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
33511946
Citation
Sharma T, Padala PR, Mehta JL. Loneliness and Social Isolation: Determinants of Cardiovascular Outcomes. Curr Cardiol Rev. 2021;17(6):e051121190873. doi: 10.2174/1573403X17666210129101845.
Results Reference
background
PubMed Identifier
33511321
Citation
Padala KP, Jendro AM, Wilson KB, Padala PR. Technology Use to Bridge the Gap of Social Distancing during COVID-19. J Geriatr Med Gerontol. 2020 Jun 29;6(2):10.23937/2469-5858/1510092. doi: 10.23937/2469-5858/1510092. No abstract available.
Results Reference
background
PubMed Identifier
32969235
Citation
Padala KP, Parkes CM, Padala PR. Neuropsychological and Functional Impact of COVID-19 on Mild Cognitive Impairment. Am J Alzheimers Dis Other Demen. 2020 Jan-Dec;35:1533317520960875. doi: 10.1177/1533317520960875.
Results Reference
background
PubMed Identifier
32925060
Citation
Padala PR, Boozer EM, Lensing SY, Parkes CM, Hunter CR, Dennis RA, Caceda R, Padala KP. Neuromodulation for Apathy in Alzheimer's Disease: A Double-Blind, Randomized, Sham-Controlled Pilot Study. J Alzheimers Dis. 2020;77(4):1483-1493. doi: 10.3233/JAD-200640.
Results Reference
background
PubMed Identifier
34099086
Citation
Preston AM, Padala PR. Virtual reality on the verge of becoming a reality for geriatric research. Int Psychogeriatr. 2022 Feb;34(2):97-99. doi: 10.1017/S1041610221000867. Epub 2021 Jun 8. No abstract available.
Results Reference
background
PubMed Identifier
34644661
Citation
Das A, Padala KP, Crawford CG, Teo A, Mendez DM, Phillips OA, Wright BC, House S, Padala PR. A systematic review of loneliness and social isolation scales used in epidemics and pandemics. Psychiatry Res. 2021 Dec;306:114217. doi: 10.1016/j.psychres.2021.114217. Epub 2021 Oct 8.
Results Reference
background
PubMed Identifier
34570180
Citation
Mintzer J, Lanctot KL, Scherer RW, Rosenberg PB, Herrmann N, van Dyck CH, Padala PR, Brawman-Mintzer O, Porsteinsson AP, Lerner AJ, Craft S, Levey AI, Burke W, Perin J, Shade D; ADMET 2 Research Group. Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial. JAMA Neurol. 2021 Nov 1;78(11):1324-1332. doi: 10.1001/jamaneurol.2021.3356.
Results Reference
background
PubMed Identifier
34315645
Citation
Mortby ME, Adler L, Aguera-Ortiz L, Bateman DR, Brodaty H, Cantillon M, Geda YE, Ismail Z, Lanctot KL, Marshall GA, Padala PR, Politis A, Rosenberg PB, Siarkos K, Sultzer DL, Theleritis C; ISTAART NPS PIA. Apathy as a Treatment Target in Alzheimer's Disease: Implications for Clinical Trials. Am J Geriatr Psychiatry. 2022 Feb;30(2):119-147. doi: 10.1016/j.jagp.2021.06.016. Epub 2021 Jul 1.
Results Reference
background
PubMed Identifier
35530116
Citation
Okolichany R, Padala PR, Mooney S. Cognitive and Functional Abilities in an Older Adult Veteran Before and After Contracting COVID-19. J Alzheimers Dis Rep. 2022 Mar 25;6(1):115-120. doi: 10.3233/ADR-210055. eCollection 2022.
Results Reference
background
PubMed Identifier
36053568
Citation
Preston AM, Brown L, Padala KP, Padala PR. Veterans Affairs Health Care Provider Perceptions of Virtual Reality: Brief Exploratory Survey. Interact J Med Res. 2022 Sep 2;11(2):e38490. doi: 10.2196/38490.
Results Reference
background
Learn more about this trial
Transcranial Magnetic Stimulation for Apathy in Mild Cognitive Impairment
We'll reach out to this number within 24 hrs